

Date: October 19, 2023

To,

NSE LIMITED

EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Outcome of Board Meeting

In compliance of Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today i.e., October 19, 2023 has inter alia, considered and approved the following business:

- i. Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the half year ended September 30, 2023. (Attached herewith as Annexure-1)
- ii. Interim Dividend for FY 2023-24 of 20% i.e. Rs.2.00 per equity share of face value of Rs.10/- each. The record date for the purpose of payment of Interim Dividend, as intimated earlier will be 28.10.2023.
- iii. Sale of stake in Associate Company (The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR / CFD / CMD / 4 / 2015, dated September 09, 2015, are given as an Annexure 2)
- iv. Setting up of own dedicated Research and Development facility for specialty and complex molecules.

Kindly note that the meeting of the Board of Directors of the Company commenced at 11:45 a.m. and concluded at 02.00 p.m.

You are requested to take the aforesaid information on your record.

Thanking you

Yours Sincerely,

For, Remus Pharmaceuticals Limited

SWAPNIL

JATINBHAI SHAH

Digitally signed by
SWAPNIL JATINBHAI SHAH
Date: 2023.10.19 14:09:27
+05'30'



Swapnil Jatinbhai Shah

Chairman and Whole Time Director

DIN: 05259821

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

**CHARTERED ACCOUNTANTS**

CA. (DR). HITEN PARIKH

M.Com., LL.B., FCA., PH.D., IP

CA. SANJAY MAJMUDAR

B.Com., LL.B., FCA

CA. SATWIK DURKAL

B.Com., FCA

CA. KOMAL MAJMUDAR

B.Com., FCA, DISA, IFRS

**Independent Auditors Review Report on the Half year and Year to Date
Unaudited Standalone Financial Results of the Company pursuant to the
Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended**

Review Report to,
The Board of Directors,
REMUS PHARMACEUTICALS LIMITED
Ahmedabad.

We have reviewed the accompanying statement of unaudited standalone financial results of **REMUS PHARMACEUTICALS LIMITED** (the "company") for the Half year ended September 30, 2023 and year to date from April 1 2023 to September 30 2023. (The "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.



We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Accounting Standard ("AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

OTHER MATTERS

The Statement includes the standalone financial results for the Six months ended September 30, 2022 which were not reviewed by us and are prepared by the management. since Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015 as amended was not applicable as on the said date.

Our opinion is not qualified in respect of this matter.

Place: AHMEDABAD

DATE: 19-10-2023



**FOR, PARIKH & MAJMUDAR
CHARTERED ACCOUNTANTS
FRN: 107525W**


(C.A SATWIK DURKAL)

PARTNER

M. No.: 107628

UDIN: 23107628BHAMWO2515

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad, Gujarat 380054
CIN: L24232GJ2015PLC084536

STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED ON 30TH SEPTMEBER, 2023					
(Rs in Lakhs except for EPS)					
	Particulars	Half year Ended			Year Ended
		30th Septmeber, 2023 (Unaudited)	31st March, 2023 (Audited)	30th September, 2022 (Unaudited)	31st March, 2023 (Audited)
I.	Revenue From Operations	2,904.08	2,455.20	2,047.53	4,502.73
II.	Other Income	165.83	72.62	85.11	157.73
III.	Total Income (I + II)	3,069.91	2,527.82	2,132.64	4,660.46
IV.	Expenses:				
	Cost of Materials Consumed	-	-	-	-
	Purchase of Stock in Trade	1,444.78	1,127.32	886.37	2,013.69
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(84.86)	21.88	108.35	130.23
	Employee Benefits Expense	329.37	355.95	191.06	547.01
	Finance Costs	9.51	20.66	2.59	23.25
	Depreciation and Amortization Expense	41.96	38.87	8.86	47.73
	Other Expenses	288.16	376.11	381.05	757.16
	Total expenses	2,028.92	1,940.79	1,578.28	3,519.07
V.	Profit before exceptional and extraordinary items and tax (III-IV)	1,040.99	587.03	554.36	1,141.39
VI.	Exceptional Items	-	-	-	-
VII.	Profit before extraordinary items and tax (V - VI)	1,040.99	587.03	554.36	1,141.39
VIII.	Extraordinary Items	-	-	-	-
IX.	Profit before tax (VII- VIII)	1,040.99	587.03	554.36	1,141.39
X	Tax expense:				
	(1) Current Tax	270.00	155.00	145.00	300.00
	(2) Deferred Tax	(6.73)	(10.82)	2.22	(8.60)
	(3) Short/(excess) Provision for Earlier Years	(3.07)	(0.29)	-	(0.29)
XI	Profit (Loss) for the period from continuing operations (VII-VIII)	780.79	443.14	407.14	850.28
XII	Profit/(loss) From Discontinuing Operations	-	-	-	-
XIII	Tax Expense of Discontinuing Operations	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	780.79	443.14	407.14	850.28
XVII	Paid up Equity Share Capital (Face value of Rs 10 per share)	147.30	108.50	100.00	108.50
	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year				1,805.05
XVI	Earnings Per Equity Share:				
	(1) Basic & Diluted (EPS not annulised for Half Year ended)	57.38	42.49	40.71	83.24

For, Remus Pharmaceuticals Limited,



Swapnil Shah

Chairman & Whole Time Director

DIN: 05259821

Date: 19-10-2023

Place: Ahmedabad

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road,
Ahmedabad Gujarat 380054
CIN: L24232GJ2015PLC084536

Notes to Standalone Financial Results:

- i The above standalone unaudited financial results for the Half year ended 30th September, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of Remus Pharmaceuticals Limited ("the Company") in their meeting held on 19th October, 2023.
- ii The above standalone unaudited Financial Results for the Half year ended on 30th Septmeber, 2023 are prepared in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Accounting) Rules, 2014 as amended and other recognized accounting practices and policies, as applicable.
- iii In accordance with Regulation 33 of the SEBI (LODR) Regulations 2015, the above standalone results have been reviewed by the Statutory Auditors of the Company for the half year ended Septmeber 30, 2023.
- iv The comparative standalone figures of the Half year ended on 30th September, 2022 have been considered based on the unaudited/unreviewed figures, since the regulations as per SEBI (LODR) Regulations, 2015, as amended from time to time, were not applicable during the said period. The Statement includes the standalone audited financial results for the half year ended March 31, 2023 being the balancing figure between the standalone audited figures in respect of the full financial year ended March 31, 2023 and the unpublished unaudited year-to-date figures up to the half year of the previous financial year.
- v EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.
- vi The Company is operating in a single segment. Hence, the above financial results are based on single segment only.
- vii The Company has raised Rs 4768.52 lakhs through issue of 388,000 shares of face value Rs 10 per share at a premium of Rs 1219 per share through initial public offer (IPO). The shares of the company got listed on NSE emerge platform as on 29th May, 2023.
- vii During the said period, the Company has one Associate company "Ratnatris Pharmaceuticals Private Limited" and there are no subsidiaries as on 30th Septmeber, 2023.
- ix The Proceeds of IPO have been utilised till September 30, 2023 as per the below mentioned table:

(Amount in Rs Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance available in HDFC Bank	Balance Available as Fixed Deposits with HDFC Bank
Public Issue Expenses	100.00	98.69	1.31	-
To Meet Working Capital Requirements	3,030.36	1,299.87	120.49	1,610.00
Funding Investment for acquisition and General Corporate Purpose	1,638.16	-	-	1,638.16
TOTAL	4,768.52	1,398.55	121.81	3,248.16

- x The Board of Directors of the company in their meeting dated 19th October, 2023 have declared interim dividend of Rs 2 per share for the FY 2023-24.
- xi The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For, Remus Pharmaceuticals Limited,

Date: 19-10-2023
Place: Ahmedabad



[Signature]

Swapnil Shah
Chairman & Whole Time Director
DIN: 05259821

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad Gujarat 380054

CIN: L24232GJ2015PLC084536

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON SEPTEMBER 30, 2023		
(Rs in Lakhs)		
Particulars	As on September 30, 2023	As on March 31, 2023
I. EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share Capital	147.30	108.50
(b) Reserves and Surplus	7,216.86	1,805.05
(c) Money received against share warrants	-	-
	7,364.16	1,913.55
2 Share application money pending allotment		
3 Non-current liabilities		
(a) Long-Term Borrowings	144.07	708.90
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long-Term Provisions	35.09	27.52
	179.16	736.42
4 Current liabilities		
(a) Short-Term Borrowings	73.56	85.38
(b) Trade Payables		
- Total Outstanding Dues for Creditors belongs to Micro & Small	463.43	273.64
- Total Outstanding Dues for Creditors other than Micro & Small	281.08	79.47
(c) Other Current Liabilities	287.57	286.93
(d) Short-Term Provisions	121.56	90.75
	1,227.20	816.17
TOTAL	8,770.51	3,466.14
II. ASSETS		
Non-current assets		
1 (a) Property, Plant & Equipment and Intangible Assets		
(i) Property, Plant & Equipments	265.38	249.07
(ii) Intangible Assets	3.90	5.03
(iii) Capital work-in-progress	-	2.18
(iv) Intangible assets under development	-	-
(b) Non-Current Investments	2,054.90	2,061.58
(c) Deferred Tax Assets (net)	19.47	12.74
(d) Long-term Loans and Advances	-	-
(e) Other Non-Current Assets	48.85	1.17
	2,392.49	2,331.77
2 Current assets		
(a) Current Investments	-	-
(b) Inventories	113.56	28.70
(c) Trade Receivables	1,519.07	484.77
(d) Cash and Cash Equivalents	4,227.88	303.82
(e) Short-Term Loans and Advances	517.51	317.09
(f) Other Current Assets	-	-
	6,378.02	1,134.38
TOTAL	8,770.51	3,466.14

Date: 19-10-2023
Place: Ahmedabad



For, Remus Pharmaceuticals Limited,

Swapnil Shah
Swapnil Shah
Chairman & Whole Time Director
DIN: 05259821

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad Gujarat 380054

CIN: L24232GJ2015PLC084536

STANDALONE STATEMENT OF CASH FLOW FOR THE PERIOD ENDED ON SEPTEMBER 30, 2023

(Rs in Lakhs)

	For the Half year ended on September 30th, 2023	For the Half year ended on March 31st, 2023
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) before Tax	1,040.98	587.03
Adjustments for :-		-
Depreciation	41.96	38.87
Interest Expense	8.35	20.66
Interest Income	(94.59)	(3.24)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	(44.28)	56.29
	996.70	643.32
Adjustments for :-		
(Increase)/Decrease in Trade Receivables	(1034.29)	(204.87)
(Increase)/Decrease in Other Current & Non-Current Assets	(47.69)	(0.09)
(Increase)/Decrease in Short term Loans & Advances	(200.42)	(97.53)
(Increase)/Decrease in Inventories	(84.86)	21.88
Increase/(Decrease) in Trade payables & Other Liabilities	430.39	(51.63)
	(936.87)	-332.24
CASH GENERATED FROM OPERATIONS	59.83	311.08
Income tax paid	(266.93)	(154.71)
	(266.93)	(154.71)
NET CASH FROM OPERATING ACTIVITIES (A)	(207.10)	156.37
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(54.95)	(70.98)
Sale of Securities	6.68	-
Purchase of Securities	-	(1754.82)
(Increase)/Decrease in Long Term Loans & Advances	-	1,324.32
Interest Income	94.59	3.24
NET CASH FLOW FROM INVESTMENT ACTIVITIES (B)	46.32	-498.24
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) in Borrowings	(576.63)	169.80
Proceeds from Issue of Shares	4,768.52	425.00
Public Issue expenditure	(98.69)	-
Interest Expense	(8.35)	(20.66)
NET CASH FLOW FROM FINANCING ACTIVITIES (C)	4,084.85	574.14
NET DECREASE IN CASH & CASH EQUIVALENTS (A+B+C)	3,924.06	232.27
Cash & Cash Equivalents at the beginning of the Year	303.82	71.54
Cash & Cash Equivalents at the end of the Year	4,227.88	303.82
Cash & Cash Equivalents Includes		
Balances in current account with scheduled banks	193.23	92.15
Balances in Fixed account with scheduled banks	4,024.61	202.52
Cash on hand	10.04	9.15
	4,227.88	303.82

For, Remus Pharmaceuticals Limited,



Date: 19-10-2023
Place: Ahmedabad

Swapnil Shah
Chairman & Whole Time Director
DIN: 05259821

CHARTERED ACCOUNTANTS

CA. (DR). HITEN PARIKH
M.Com., LL.B., FCA., PH.D., IP
CA. SANJAY MAJMUDAR
B.Com., LL.B., FCA
CA. SATWIK DURKAL
B.Com., FCA
CA. KOMAL MAJMUDAR
B.Com., FCA, DISA, IFRS

**Independent Auditors Review Report on the Half year and year to date
Unaudited Consolidated Financial Results of the Company pursuant to the
Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended**

Review Report to,

The Board of Directors

**REMUS PHARMACEUTICALS LTD
Ahmedabad.**

We have reviewed the accompanying statement of unaudited consolidated financial results of **REMUS PHARMACEUTICALS LIMITED** (the "company") and its associates (to gether the group) for the Half year ended September 30, 2023 and year to date from April 1 2023 to September 30 2023. (the "statement") attached herewith, being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, as amended (the listing Regulation) .

This Statement is the responsibility of the Company's Management and is approved by the Board of Directors has been prepared in accordance with Accounting Standard 25 "Interim Financial Reporting" ("AS 25") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review.



We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, to the extent applicable.

The statement includes the results of the following entities

Parent Company/Holding Company :

i. REMUS PHARMACEUTICALS LIMITED

Associates :

i. RATNATRIS PHARMACEUTICALS PRIVATE LIMITED.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Accounting Standard ("AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement

Date: 19-10-2023

Place: Ahmedabad



For Parikh & Majmudar

Chartered Accountants

FRNNO 107525W

C.A SATWIK DURKAL

PARTNER

M.No. 107628

UDIN: 23107628BHAMWP5323

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad, Gujarat, 380054
CIN: L24232GJ2015PLC084536

CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED ON 30TH SEPTMEBER, 2023		
(Rs in Lakhs except for EPS)		
Particulars		For the Half Year Ended Septmeber 30, 2023
I.	Revenue From Operations	2,904.08
II.	Other Income	165.83
III.	Total Income (I + II)	3,069.90
IV.	Expenses:	
	Cost of Materials Consumed	-
	Purchase of Stock in Trade	1,444.78
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(84.86)
	Employee Benefits Expense	329.37
	Finance Costs	9.51
	Depreciation and Amortization Expense	41.96
	Other Expenses	288.16
	Total expenses	2,028.92
V.	Profit before exceptional and extraordinary items and tax (III-IV)	1,040.99
VI.	Exceptional Items	-
VII.	Profit before extraordinary items and tax (V - VI)	1,040.99
VIII.	Extraordinary Items	-
IX.	Profit before tax (VII- VIII)	1,040.99
X	Tax expense:	
	(1) Current Tax	270.00
	(2) Deferred Tax	(6.73)
	(3) Short/(excess) Provision for Earlier Years	(3.07)
XI	Profit (Loss) for the period from continuing operations (VII-VIII)	780.79
XII	Profit/(loss) From Discontinuing Operations	-
XIII	Tax Expense of Discontinuing Operations	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-
XV	Profit/(loss) for the period (after Tax) (XI + XIV)	780.79
XVI	Share of Profit/(Loss) of Associates	(216.03)
XVII	Profit/(loss) for the period (after Tax) after Share of Profit/(Loss) of Associates (XV + XVI + XVII)	564.76
XVII	Paid up Equity Share Capital (Face value of Rs 10 per share)	147.30
	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-
XVIII	Earnings Per Equity Share:	
	(1) Basic & Diluted (EPS not annulised for Half Year ended)	41.51

Date: 19-10-2023
Place: Ahmedabad



For, Remus Pharmaceuticals Limited,

Swapnil Shah
Swapnil Shah
Chairman & Whole Time Director
DIN: 05259821

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad
Gujarat 380054
CIN: L24232GJ2015PLC084536

Notes to Consolidated Financial Results:

- i The above consolidated unaudited financial results for the Half year ended 30th September, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of Remus Pharmaceuticals Limited ("the Company") in their meeting held on 19th October, 2023.
- ii The above Consolidated unaudited Financial Results for the Half year ended on 30th September, 2023 are prepared in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Accounting) Rules, 2014 as amended and other recognized accounting practices and policies, as applicable.
- iii In accordance with Regulation 33 of the SEBI (LODR) Regulations 2015, the above consolidated results have been reviewed by the Statutory Auditors of the Company for the half year ended September 30, 2023.
- iv Ratnatris Pharmaceuticals Private Limited became an associate of the Company during current period in FY 23-24. There was no consolidation of financials during corresponding previous period or the year. Provisions for presenting Consolidated results for previous period/year are not applicable and hence comparative figures for the said period/year are not given.
- v EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.
- vi The Company is operating in a single segment. Hence, the above financial results are based on single segment only.
- vii The Company has raised Rs 4768.52 lakhs through issue of 388,000 shares of face value Rs 10 per share at a premium of Rs 1219 per share through initial public offer (IPO). The shares of the company got listed on NSE emerge platform as on 29th May, 2023.
- viii The Proceeds of IPO have been utilised till September 30, 2023 as per the below mentioned table:

(Amount in Rs Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance available in HDFC Bank	Balance Available as Fixed Deposits with HDFC Bank
Public Issue Expenses	100.00	98.69	1.31	-
To Meet Working Capital Requirements	3,030.36	1,299.87	120.49	1,610.00
Funding Investment for acquisition and General Corporate Purpose	1,638.16	-	-	1,638.16
TOTAL	4,768.52	1,398.55	121.81	3,248.16

- ix The Board of Directors of the company in their meeting dated 19th October, 2023 have declared interim dividend of Rs 2 per share for the FY 2023-24.
- xi The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

Date: 19-10-2023
Place: Ahmedabad



For, Remus Pharmaceuticals Limited,

Swapnil Shah
Chairman & Whole Time Director
DIN: 05259821

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad Gujarat 380054
CIN: L24232GJ2015PLC084536

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON SEPTEMBER 30, 2023	
(Rs in Lakhs)	
Particulars	As on September 30, 2023
I. EQUITY AND LIABILITIES	
1 Shareholders' funds	
(a) Share Capital	147.30
(b) Reserves and Surplus	7,000.82
(c) Money received against share warrants	
	7,148.12
2 Share application money pending allotment	
3 Non-current liabilities	
(a) Long-Term Borrowings	144.07
(b) Deferred Tax Liabilities (Net)	-
(c) Other Long Term Liabilities	-
(d) Long-Term Provisions	35.09
	179.16
4 Current liabilities	
(a) Short-Term Borrowings	73.56
(b) Trade Payables	
- Total Outstanding Dues for Creditors belongs to Micro & Small Enterprises	463.43
- Total Outstanding Dues for Creditors other than Micro & Small Enterprises	281.08
(c) Other Current Liabilities	287.57
(d) Short-Term Provisions	121.56
	1,227.20
TOTAL	8,554.48
II. ASSETS	
Non-current assets	
1 (a) Property, Plant & Equipment and Intangible Assets	
(i) Property, Plant & Equipments	265.38
(ii) Intangible Assets	3.90
(iii) Capital work-in-progress	-
(iv) Intangible assets under development	-
(b) Non-Current Investments	1,838.87
(c) Deferred Tax Assets (net)	19.47
(d) Long-term Loans and Advances	-
(e) Other Non-Current Assets	48.85
	2,176.46
2 Current assets	
(a) Current Investments	-
(b) Inventories	113.56
(c) Trade Receivables	1,519.07
(d) Cash and Cash Equivalents	4,227.88
(e) Short-Term Loans and Advances	517.51
(f) Other Current Assets	-
	6,378.02
TOTAL	8,554.48

Date: 19-10-2023
Place: Ahmedabad



For, Remus Pharmaceuticals Limited,

[Signature]

Swapnil Shah
Chairman & Whole Time Director
DIN: 05259821

Remus Pharmaceuticals Limited

(Formerly known as "Remus Pharmaceuticals Private Limited")

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road,
Ahmedabad Gujarat 380054
CIN: L24232GJ2015PLC084536

CONSOLIDATED STATEMENT OF CASH FLOW FOR THE PERIOD ENDED ON SEPTEMBER 30, 2023	
	(Rs in Lakhs)
	For the Half year ended on September 30th, 2023
A. CASH FLOW FROM OPERATING ACTIVITIES	
Net Profit/(Loss) before Tax	1,040.98
Adjustments for :-	
Depreciation	41.96
Interest Expense	8.35
Interest Income	(94.59)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	(44.28)
	996.70
Adjustments for :-	
(Increase)/Decrease in Trade Receivables	(1034.29)
(Increase)/Decrease in Other Current & Non-Current Assets	(47.69)
(Increase)/Decrease in Short term Loans & Advances	(200.42)
(Increase)/Decrease in Inventories	(84.86)
Increase/(Decrease) in Trade payables & Other Liabilities	430.39
	(936.87)
CASH GENERATED FROM OPERATIONS	59.83
Income tax paid	(266.93)
	(266.93)
NET CASH FROM OPERATING ACTIVITIES (A)	(207.10)
B. CASH FLOW FROM INVESTING ACTIVITIES	
Purchase of Fixed Assets	(54.95)
Sale of Securities	6.68
Purchase of Securities	-
(Increase)/Decrease in Long Term Loans & Advances	-
Dividend Income	-
NET CASH FLOW FROM INVESTMENT ACTIVITIES (B)	46.32
C. CASH FLOW FROM FINANCING ACTIVITIES	
Increase/(Decrease) in Borrowings	(576.63)
Proceeds from Issue of Shares	4,768.52
Public Issue expenditure	(98.69)
Interest Expense	(8.35)
NET CASH FLOW FROM FINANCING ACTIVITIES (C)	4,084.85
NET DECREASE IN CASH & CASH EQUIVALENTS (A+B+C)	3,924.06
Cash & Cash Equivalents at the beginning of the Year	303.82
Cash & Cash Equivalents at the end of the Year	4,227.88
Cash & Cash Equivalents Includes	
Balances in current account with scheduled banks	193.23
Balances in Fixed account with scheduled banks	4,024.61
Cash on hand	10.04
	4,227.88

For, Remus Pharmaceuticals Limited,



Date: 19-10-2023
Place: Ahmedabad

[Signature]
Swapnil Shah
Chairman & Whole Time Director
DIN: 05259821

Annexure-02

Details required under Regulation 30 of SEBI (LODR) Regulations, 2015 read along with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015

	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	Ratnatris Pharmaceuticals Private Limited, was not an associate company during the financial year ended March 31,2023. Hence, amount and percentage of contribution is not applicable.
2.	Date on which the agreement for sale has been entered into	The Company will enter into a definitive agreement for Share Swap transaction with Senores Pharmaceuticals Limited (Transferee Company) upon approval of shares swap transaction by the members of Transferee Company.
3.	The expected date of completion of sale/ disposal.	Within 02 Months
4.	Consideration received from such sale/ disposal.	The Company shall receive 3261244 number of Equity Shares of Senores Pharmaceuticals Limited.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	The entire stake will be purchased by Senores Pharmaceuticals Limited (SPL). SPL belongs to the promoter group companies and the said transaction is done at the arms length basis. The transaction would be a related party transaction. The swap ratio has been determined based on the valuation report obtained from independent valuer.
6.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation / merger, shall be disclosed by the listed entity with respect to such slump sale	Not applicable

SWAPNIL

JATINBHAI SHAH

Digitally signed by SWAPNIL
JATINBHAI SHAH
Date: 2023.10.19 14:11:30
+05'30'

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536